Private equity-controlled J B Chemicals and Pharmaceuticals, which recently snapped up a basket of ophthalmology brands from Novartis in India, expects to drive momentum to make key product franchises bigger and stronger, while also building on the CDMO business.
A sprinkling of Indian firms docked in at the J.P. Morgan Healthcare Conference 2024 outlining what to expect amid industry headwinds, geopolitical tensions and an election year on the home market. (Also see "J.P. Morgan 2024: Optimism With An Undercurrent Of Tension" - Scrip, 11 January, 2024.)
One such company and serial acquirer JB Chemicals & Pharmaceuticals Ltd., highlighted strides made on domestic turf and abroad,...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
